Ingest podcast

#Science #Podcasting Education #Medicine #The Primary Care Society for Gastroenterology

34:35

Marcia Clark, best known as the lead prosecutor in the O.J. Simpson trial, has become a trailblazer for women in law and beyond. Her journey from courtroom to bestselling author reflects her resilience and determination to redefine herself amidst intense public scrutiny. On this episode of Worth Knowing, Clark dives into her latest book, *Trial by Ambush*, which examines the 1953 Barbara Graham case—a story that highlights gender bias, media sensationalism, and the notion that all cases are subject to societal, cultural, and political winds. Clark shares how her experiences during the Simpson trial shaped her perspective on societal pressures and the role of women in high-stakes professions. Her reflections on how media, forensic science, and legal practices have evolved over decades offer valuable insights into the intersection of law and culture. This conversation is a compelling exploration of true crime, personal growth, and how Clark’s groundbreaking career continues to inspire a new generation of women to challenge norms and forge their own paths. Marcia Clark is a bestselling author and a criminal lawyer who began her career in law as a criminal defense attorney and went on to become a prosecutor in the L.A. District Attorney's Office in 1981. She spent ten years in the Special Trials Unit, where she handled a number of high-profile cases, including the prosecution of stalker/murderer Robert Bardo, whose conviction for the murder of actress Rebecca Schaeffer resulted in legislation that offered victims better protection from stalkers as well as increased punishment for the offenders. She was lead prosecutor for the O.J. Simpson murder trial. In May of 1997 her book on the Simpson case, "Without a Doubt," was published and reached #1 on the New York Times, Wall St. Journal, Washington Post, Los Angeles Times, and Publishers Weekly bestsellers lists. In February 2016, Clark re-released the book with a new foreword. Resources Sign up for the Worth Knowing LinkedIn Newsletter to stay up to date: https://www.linkedin.com/newsletters/worth-knowing-7236433935503618048/ Follow Bonnie on LinkedIn: https://www.linkedin.com/in/bonnie-habyan/ Go to the Worth Knowing website: https://www.worthknowing.show Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company…

Ingest

Поширити

Головна серій•Feed

Dr Charlie Andrews, a GP from Bath and PCSG Committee Member, explores a range of gastroenterology topics from a GPs perspective. The focus of the series covers when to suspect, how to diagnose, when to refer and how to support your patients.

30 епізодів

Ingest

updated рік тому

Поширити

Головна серій•Feed

30 епізодів

#Science #Podcasting Education #Medicine #The Primary Care Society for Gastroenterology

Усі епізоди

Ingest

1
Neuroendocrine Cancer – The Expert Patient 43:29

6 weeks тому43:29

43:29

The episode features Dr. David Bartlett, a retired GP and neuroendocrine cancer patient, offering a dual perspective as both clinician and patient. Key Learnings from this episode. Patient Experience and Diagnostic Challenges Dr. Bartlett’s symptoms began with severe, intermittent abdominal pain, starting in 2001, but he did not seek medical help for several years due to a combination of stoicism, not wanting to trouble others, and a belief in the commonality of benign causes. Over 15 years, he experienced repeated misdiagnoses, primarily being labeled as having irritable bowel syndrome (IBS) despite atypical features (severe pain, minimal bowel habit change, and no systemic symptoms). Multiple opinions and investigations (including ultrasounds and CT scans) failed to identify the underlying cause, with a key scan being misread by local radiologists. The correct diagnosis of a small bowel neuroendocrine tumour was only made after a tertiary centre re-examined previous scans, highlighting the importance of specialist review and persistence in unexplained cases. Clinical Red Flags and Symptomatology Dr. Bartlett’s case underscores that neuroendocrine tumors can present with isolated, severe abdominal pain without classic red flags (vomiting, weight loss, significant bowel changes)[1]. He retrospectively identified subtle signs of carcinoid syndrome (flushing, one episode of profound diarrhoea, and skin changes), which are present in only about 10% of small bowel neuroendocrine tumour cases. The lack of awareness about neuroendocrine tumors, even among experienced clinicians, contributed to the diagnostic delay[1]. Lessons for Primary Care and Clinicians The story illustrates the risk of anchoring on common diagnoses (like IBS) and the need to reconsider the diagnosis when symptoms are severe, persistent, or atypical. It highlights the value of listening to the patient’s narrative, especially when symptoms do not fit classic patterns, and the importance of considering rare conditions in the differential diagnosis. The episode emphasises the need for ongoing education about neuroendocrine tumours and the importance of keeping rare but serious conditions on the diagnostic radar in primary care. Management Insights Standard treatment for small bowel neuroendocrine tumours often includes monthly somatostatin analog injections (e.g., lanreotide). Surgical intervention may be considered, but it carries specific risks such as carcinoid crisis, requiring specialised perioperative management. The decision for surgery is individualised, weighing potential symptomatic improvement against procedural risks. Systemic and Human Factors Dr. Bartlett’s experience reflects how personal traits (stoicism, reluctance to seek help) and systemic issues (misinterpretation of scans, diagnostic inertia) can delay diagnosis. The narrative also demonstrates the importance of patient advocacy, persistence, and the value of second (or third) opinions, especially in complex or unresolved cases. Educational Value The episode serves as a reminder for clinicians to maintain a broad differential, revisit diagnoses when the clinical picture changes, and to be aware of their own cognitive biases. It also advocates for the inclusion of patient voices in medical education to better understand the lived experience and challenges of rare diseases like neuroendocrine cancer. Summary Table: Key Learnings ThemeKey PointsDiagnostic Delay15 years from symptom onset to diagnosis; misdiagnosed as IBS despite atypical featuresSymptomatologySevere, intermittent abdominal pain; minimal bowel changes; subtle carcinoid syndromeClinical LessonsImportance of specialist review, reconsidering diagnoses, and listening to patient storiesManagementUse of somatostatin analogs; surgery considered but with specific risksSystemic FactorsImpact of stoicism, misread scans, and diagnostic inertiaEducational TakeawayNeed for awareness of rare conditions and patient-centered education These insights from the transcript highlight the complexities of diagnosing and managing neuroendocrine cancer, especially in primary care, and the critical role of patient experience in improving clinical practice.…

Ingest

1
Pancreatic Conditions Part 2 – Malignant 43:36

9 weeks тому43:36

43:36

Dr Charlie Andrews talks to Dr John Leeds. John Leeds is a Consultant Pancreaticobiliary Physician and Endoscopist based at the Freeman Hospital in Newcastle and an Honorary Clinical Senior Lecturer based in the Population Health Sciences Institute at Newcastle University. He is involved in research in pancreaticobiliary disorders including benign and malignant conditions as well as outcomes from therapeutic/advanced endoscopy. John is a member of the British Society of Gastroenterology and Pancreatic Society of Great Britain and Ireland. He serves on the endoscopy and Pancreas committees for BSG and is the website lead for PSGBI. He is also a founder member of the BSG Pancreas Clinical Research Group which is coordinating research for the society. Key Learnings from this episode: Challenges in Early Detection of Pancreatic Cancer • Pancreatic cancer is often diagnosed at an advanced stage due to the deep location of the pancreas and the lack of early symptoms. • Tumors in the body and tail of the pancreas can grow significantly before causing symptoms, often invading major arteries or veins, making them inoperable. • Tumors in the head of the pancreas may present earlier due to bile duct obstruction, leading to jaundice, but even these are often detected late. Early Symptoms and Red Flags • Early symptoms are vague or absent, making early diagnosis difficult. • Possible early indicators include: • Weight loss (often a sign of advanced disease). • New-onset diabetes, particularly in individuals with a normal BMI or without typical risk factors for type 2 diabetes. • Jaundice, which is a significant red flag and often indicates a serious underlying condition. • Classic signs like painless jaundice and Courvoisier’s sign (palpable gallbladder) are important but not always present. Limitations of Current Screening Methods • There is no reliable biomarker or screening test for pancreatic cancer: • CA19-9 is not suitable as a screening tool due to its lack of specificity (elevated in other conditions). • Imaging techniques like CT scans or MRIs are used but have limitations, including incidental findings that may lead to unnecessary anxiety (“scanxiety”) and over-investigation. • Screening is currently limited to high-risk groups, such as those with familial pancreatic cancer syndromes or hereditary pancreatitis. High-Risk Groups for Screening • Familial pancreatic cancer accounts for less than 10% of cases. Criteria for screening include: • Multiple family members with pancreatic cancer, especially diagnosed under age 50–60. • Genetic syndromes like BRCA mutations, familial adenomatous polyposis (FAP), and Peutz-Jeghers syndrome. • Hereditary pancreatitis patients have an increased risk but are harder to screen due to pre-existing pancreatic abnormalities. Emerging Research and Future Directions • Studies are exploring potential biomarkers, such as microbiome signatures in the pancreas, which might help identify high-risk individuals in the future. • Trials like the EuroPAC study focus on surveillance protocols for high-risk individuals using imaging techniques like MRI or endoscopic ultrasound. • Research into new-onset diabetes as a potential marker for pancreatic cancer is ongoing but currently has a low yield due to the high prevalence of type 2 diabetes unrelated to malignancy. Considerations for Screening and Surveillance • Screening should be carefully targeted to avoid over-diagnosis and unnecessary investigations. • The psychological impact of screening (e.g., anxiety from incidental findings) must be considered. • Smoking cessation is emphasized as smoking is a significant risk factor for pancreatic cancer. Advances in Treatment Approaches • PET-CT scans are increasingly used to detect systemic disease that might not be evident on standard CT scans. • Neoadjuvant treatments (therapy before surgery) are being explored for cases where systemic spread is suspected. Conclusion Pancreatic cancer remains challenging to detect early due to vague symptoms and limited screening tools. Current efforts focus on identifying high-risk groups for targeted surveillance and advancing research into biomarkers and new diagnostic strategies. Early detection remains critical for improving outcomes, but significant barriers persist.…

Ingest

1
Pancreatic Conditions Part 1 – Benign 1:08:41

11 weeks тому1:08:41

1:08:41

Ingest

1
IBS Part 2 – Management 45:15

15 weeks тому45:15

45:15

Charlie Andrews talks to Dr Chris Black about the management of IBS. This podcast provides key insights into managing Irritable Bowel Syndrome (IBS), emphasising a multidisciplinary and individualised approach to care. Here are the main takeaways: 1. Multidisciplinary and Integrative Care IBS management requires a holistic, patient-centered approach involving dietitians, behavioral therapists, and gastroenterologists. This "team sport" approach expands treatment options and tailors care to individual patient needs 1 . Integrative care, which combines dietary, psychological, and medical interventions, has been shown to improve symptoms, psychological well-being, and quality of life for IBS patients 1 . 2. Personalised Treatment IBS is not a one-size-fits-all condition. There are different subtypes of IBS (e.g., IBS-D for diarrhea-predominant or IBS-C for constipation-predominant), and treatment must be customized based on the patient's symptoms and triggers 4 . Emerging research suggests the need to identify distinct subtypes of IBS to guide more effective treatments 2 4 . 3. Dietary Management The low FODMAP diet is a widely recommended dietary intervention for IBS. It helps identify food triggers and manage symptoms but should not be used long-term without personalization 3 . Probiotics may also play a role in symptom relief for some patients, though their effectiveness varies 3 . 4. Behavioral Interventions Cognitive Behavioral Therapy (CBT) and gut-directed hypnotherapy are effective in managing IBS symptoms, particularly when patients are motivated to engage in these therapies 1 . Stress management is critical since stress and anxiety can exacerbate IBS symptoms 1 5 . 5. Pharmacological Therapies Medications are often used as complementary treatments when dietary or behavioral strategies alone are insufficient. These include antispasmodics, laxatives, or medications targeting gut-brain interaction 1 5 . Precision medicine is the future of pharmacological treatment, aiming to match therapies with the underlying causes of an individual's symptoms rather than just addressing the symptoms themselves 1 . 6. Challenges in IBS Management One of the most distressing symptoms for patients is bowel urgency, significantly impacting their quality of life. Research is ongoing to better understand and manage this symptom 2 4 . Pain management remains a critical area for improvement, as existing treatments often provide inadequate relief for abdominal pain and gut hypersensitivity in IBS patients 2 4 . 7. Patient Education and Collaboration Educating patients about the trial-and-error nature of IBS treatment helps set realistic expectations and reduces frustration when initial interventions do not work 1 . Shared decision-making between healthcare providers and patients ensures that treatment plans align with patient preferences and lifestyle. In summary, effective IBS management combines personalized care with dietary, behavioral, and pharmacological strategies within an integrative framework. The podcast underscores the importance of ongoing research to refine treatments and improve outcomes for IBS sufferers.…

Ingest

1
Abdominal Pain in Children 58:07

29 weeks тому58:07

58:07

Charlie Andrews talks to Dr Anthony (Tony) Wisken, Consultant Paediatric Gastroenterologist in Bristol. The Ingest podcast is hosted by Dr Charlie Andrews a GPwER in gastroenterology based near Bath. Charlie works as a GP partner at Somer Valley Medical Group, trained as an endoscopist and leads the national GPwER in gastroenterology training programme, launched in 2023 in the southwest of England. Charlie is a committee member of the PCSG (Primary Care Society of Gastroenterology). For more information visit pcsg.org.uk…

Ingest

1
Getting It Right First Time. Gastro Innovation in Northumbria 55:46

32 weeks тому55:46

55:46

With significant waiting lists and growing demand for secondary care services, Advice and Guidance is being increasingly explored as one potential solution to this problem. In this episode, Charlie Andrews discusses an innovative and extremely successful use of advice and guidance in Northumbria with gastroenterologists Matthew Warren and Richard Thomson. Through the enhanced use of advice and guidance for all incoming referrals for secondary care input, they have demonstrated a significant reduction in waiting times for routine outpatient care. They discuss their advice and guidance model, and what they have learned from developing this service and the impact it has been having on their waiting times, and how it has been received by primary care colleagues (3:30). We go on to discuss some common advice and guidance queries that Matt and Richard see (19:30) and I ask the question - what makes a good advice and guidance query? (43.30).…

Ingest

1
IBS Part 1 – Diagnosis 42:11

35 weeks тому42:11

42:11

Key takeaways from the IBS Part 1 episode of the PCSG Ingest podcast: Diagnosis of IBS The episode is focused on making a diagnosis of Irritable Bowel Syndrome (IBS)and features Dr. Anton Emmanuel, a consultant gastroenterologist and Professor of neuro-gastroenterology at University College Hospital London. Importance for Primary Care IBS is a common condition that primary care clinicians need to have a structured approach to diagnosing. Topics Covered Causes of IBS Different subtypes of IBS Challenges in making a positive diagnosis Clinical Pearls Dr. Emmanuel shares several insights: Key questions to include in the patient history How to describe the condition to patients Practical tips for enhancing IBS diagnosis in primary care Diagnostic Approach The episode emphasises the importance of: Taking a structured approach to diagnosis Understanding the various presentations of IBS Recognizing the challenges in making a definitive diagnosis Patient Communication Guidance is provided on: Explaining IBS to patients effectively Addressing patient concerns and misconceptions Additional Resources The episode mentions useful guidance from the British Society of Gastroenterology, which listeners were encouraged to reference for more detailed information. Part 2 focusing on the management of IBS to be released soon. bsg.org.uk/clinical-resource/british-society-of-gastroenterology-guidelines The Ingest podcast is hosted by Dr Charlie Andrews a GPwER in gastroenterology based near Bath. Charlie works as a GP partner at Somer Valley Medical Group, trained as an endoscopist and leads the national GPwER in gastroenterology training programme, launched in 2023 in the southwest of England. Charlie is a committee member of the PCSG (Primary Care Society of Gastroenterology). For more information visit pcsg.org.uk…

Ingest

1
High Iron Levels (hyperferritinaemia) 39:18

42 weeks тому39:18

39:18

Dr Charlie Andrews speaks to Dr Jeremy Shearman about everything related to high iron levels (hyperferritinaemia). We discuss how iron is regulated within the body, causes of raised iron levels, and then we dive into hereditary haemochromatosis - when to suspect, how to test, who to refer (and to whom!), and how the condition is managed. Useful links to accompany this episode include: Welcome > Haemochromatosis: genetic iron overload disease (exeter.ac.uk) Haemochromatosis - British Liver Trust Key Learnings for Primary Care from the Ingest Podcast on Hyperferritinaemia Key Learnings Understanding Iron Regulation and Ferritin Ferritin is an acute-phase reactant and a marker of total body iron stores, but can be elevated in a range of conditions beyond iron overload, including inflammation, liver disease, and malignancy[2]. Understanding the physiological regulation of iron is crucial for interpreting ferritin results in context. Causes of Hyperferritinaemia Raised ferritin can result from: Hereditary haemochromatosis (genetic iron overload) Chronic inflammatory states (e.g., infection, autoimmune disease) Liver disease (e.g., alcoholic liver disease, hepatitis) Malignancy Metabolic syndrome It is important to consider these differential diagnoses when encountering an elevated ferritin[2]. Hereditary Haemochromatosis: When to Suspect Primary care clinicians should suspect hereditary haemochromatosis in patients with persistently raised ferritin and transferrin saturation, especially with suggestive symptoms (e.g., fatigue, arthralgia, diabetes, liver dysfunction) or family history[2]. Early recognition is key, as treatment can prevent complications. How to Test Initial investigations should include: Repeat ferritin measurement to confirm persistence Transferrin saturation (TSAT): TSAT >45% is suggestive of iron overload Liver function tests and assessment for other causes of raised ferritin[2] If hereditary haemochromatosis is suspected, genetic testing (HFE gene) should be considered. Who to Refer (and to Whom) Refer patients with confirmed iron overload (high ferritin and TSAT) or positive HFE mutation to hepatology or a relevant specialist for further assessment and management[2]. Referral is also warranted if there are signs of organ involvement (e.g., abnormal LFTs, diabetes, cardiac symptoms). Management Principles For hereditary haemochromatosis, mainstay of treatment is venesection (therapeutic phlebotomy) to reduce iron stores. Primary care plays a role in monitoring, supporting adherence, and managing comorbidities. For other causes, management is directed at the underlying condition. Practical Tips for Primary Care Do not ignore isolated raised ferritin-always interpret in clinical context. Exclude common secondary causes (infection, inflammation, liver disease) before pursuing rare diagnoses. Family screening may be appropriate in hereditary haemochromatosis cases[2]. Use local guidelines and specialist advice where available. Summary Table: Approach to Hyperferritinaemia in Primary Care StepAction/ConsiderationConfirm raised ferritinRepeat test; assess for acute illness/inflammationAssess clinical contextSymptoms, family history, risk factorsAdditional testsTransferrin saturation, LFTs, CRP/ESRExclude secondary causesInflammation, liver disease, malignancy, metabolic syndromeSuspect haemochromatosisPersistently high ferritin + TSAT >45% ± symptoms/family historyGenetic testingHFE gene mutation if indicatedReferralTo hepatology/haematology if iron overload or organ involvementManagementVenesection for haemochromatosis; treat underlying cause for secondary hyperferritinaemia These learnings equip primary care clinicians to approach hyperferritinaemia systematically, ensuring timely diagnosis, appropriate investigation, and effective referral and management[2][5]. Sources [1] INGEST – PCSG - The Primary Care Society for Gastroenterology https://www.pcsg.org.uk/ingest/ [2] High Iron Levels (hyperferritinaemia) – PCSG https://www.pcsg.org.uk/podcast/high-iron-levels-hyperferritinaemia/ [3] Ingest - The Primary Care Society for Gastroenterology https://www.pcsg.org.uk/feed/podcast/ingest/ [4] Ingest | Podcast on Spotify https://open.spotify.com/show/365S1VrwrkHmMdTJcVl9eh [5] High Iron Levels (hyperferritinaemia) - Apple Podcasts https://podcasts.apple.com/gb/podcast/high-iron-levels-hyperferritinaemia/id1605807130?i=1000664825288 [6] Course: Searchable table - RCPE Education Portal https://learning.rcpe.ac.uk/course/view.php?id=1427 [7] Ingest Podcast – Apple Podcasts https://podcasts.apple.com/at/podcast/ingest/id1605807130 [8] High Iron Levels (hyperferritinaemia) - Ingest | Podcast on Spotify https://open.spotify.com/episode/1lQiNpVAQbEtBKiUVdiKXj [9] Ingest Trailer - Castos https://ingest.castos.com/episodes/ingest-trailer [10] Rheumatology-TP 1..2 - Oxford Academic https://academic.oup.com/rheumatology/issue-pdf/61/Supplement_1/43461770 [11] Ingest - Podcast Addict https://podcastaddict.com/podcast/ingest/4281648 [12] Diverticular disease and diverticulitis - Ingest - Castos https://ingest.castos.com/episodes/diverticular-disease-and-diverticulitis [13] Untitled https://www.audible.in/podcast/Ingest/episodes/B09QTRKTPN [14] Intensive Care Society State of the Art (SOA) 2022 Abstracts, 2023 https://journals.sagepub.com/doi/full/10.1177/17511437231156066 [15] Ingest - Apple Podcasts https://podcasts.apple.com/ch/podcast/ingest/id1605807130 [16] Ingest - Apple Podcasts https://podcasts.apple.com/gb/podcast/ingest/id1605807130…

Ingest

1
Diverticular disease and diverticulitis 22:30

48 weeks тому22:30

22:30

In this episode, Charlie Andrews speaks to Melanie Orchard, a consultant surgeon, about diverticular disease and diverticulitis. This is something that we encounter frequently in primary care, and understanding how to approach this condition is extremely important. Melanie discusses a really pragmatic approach to patients with symptoms suggestive of diverticulitis. We discuss risk factors, presenting features, and how to assess the patient with suspected diverticulitis. We also discuss the difference between diverticulosis, diverticular disease and diverticulitis, and give you useful tips on what advice to give to patients who has just had a colonoscopy showing that they have diverticulosis. For a useful visual summary of the management of patients with diverticulosis and diverticulitis, please follow this link: visual-summary-pdf-6968965213 (nice.org.uk)…

Ingest

1
Hepatitis C 32:08

1 year тому32:08

32:08

Join Charlie Andrews as he discusses Hepatitis C with hepatologist Dr Kosh Agarwal and GP and clinical champion for Hepatitis C Dr Rik Fijten. They discuss the prevalence and presentation of Hepatitis C, as well as how to test for the condition along with an overview of the treatment options available. Hepatitis C is a chronic liver disease which carries significant morbidity and mortality if left untreated. Fortunately, it is both easy to test for and the treatments available offer a fantastic cure rate of in excess of 95% with simple and relatively short tablet regimens. NHS England has set itself the target of eradicating the disease by 2025 through active case finding, simplifying the diagnostic process, and ensuring pathways are in place to provide rapid and effective treatments for the condition. Resources: For more information on Hepatitis C, the British Liver Trust offers useful patient-friendly leaflets and further information about the condition: Hepatitis C - British Liver Trust The self-testing portal mentioned by Rik during the episode can be found here: Home - HepC (hepctest.nhs.uk)…

Ingest

1
Neuroendocrine tumours (NETs) of the gastrointestinal tract 31:12

1 year тому31:12

31:12

In this episode, Dr Charlie Andrews speaks to Professor Mark Pritchard about neuroendocrine tumours (NETs) of the gastrointestinal tract. You may be asking yourself: 'Do I really need to know about NETs in primary care, aren't they extremely rare?' The answer to that is a resounding yes, you do need to know about NETs and Mark will tell you why in this episode! Neuroendocrine cancer is the 10th most prevalent cancer in England, and the second most prevalent cancer of the GI tract, with a rapidly rising incidence (371%) over the last 20 years. NETs are commonly diagnosed at a more advanced stage due to late diagnosis as the signs and symptoms can be vague, or mimic other more common conditions such as IBS. Mark provides lots of useful, practical advice about when to suspect this form of cancer in primary care, which patients may be a higher risk, and what to do if you are suspicious about this form of cancer in your patient. Listen on to find out more.…

Ingest

1
Ingest Trailer 2:53

1 year тому2:53

2:53

Dr Charlie Andrews, a committee member of the Primary Care Society for Gastroenterology (PCSG), introduces Ingest , the podcast for primary care that focuses on when to suspect, how to diagnose and how to manage common gastrointestinal presentations and conditions.

Ingest

1
Highlights from Ingest 2023 31:28

1 year тому31:28

31:28

In this episode Dr Charlie Andrews looks back at 2023 and highlights some key takeaways from Ingest in 2023.

Ingest

1
Barrett’s oesophagus 28:21

2 years тому28:21

28:21

In this episode, Charlie Andrews speaks to Dr Andrew Moore about this condition, which affects up to 1.5% of the population, with a risk of progression to cancer of 3-13% over the patient's lifetime (Cancer Research UK). They discuss the typical presenting features, who needs an endoscopy to look for Barrett's, and how the condition is managed both in primary and secondary care. The BSG guidelines mentioned by Dr Moore in the episode can be found here: https://www.bsg.org.uk/clinical-resource/bsg-guidelines-on-the-diagnosis-and-management-of-barretts-oesophagus/ For more episodes about the oesophagus, you may find the following episodes of Ingest useful: Dyspepsia, Eosinophilic oesophagitis, Dysphagia and Achalasia. BSG guidelines on the diagnosis and management of Barrett's oesophagus - The British Society of Gastroenterology Fitzgerald RC, di Pietro M, Ragunath K et al. Abstract These guidelines provide a practical and evidence-based resource for the management of patients with Barrett’s oesophagus and related early neoplasia. The Appraisal of Guidelines for Research and Evaluation (AGREE II) […] www.bsg.org.uk…

Ingest

1
Bile acid diarrhoea 27:37

2 years тому27:37

27:37

In this episode, Charlie Andrews speaks to Professor Julian Walters about bile acid malabsorption and diarrhoea. With up to a third of patients with diarrhoea-predominant IBS having underlying bile acid diarrhoea, and with diagnosis rates for this condition being low, this episode is an important one for anyone working in primary care. We explore the role and physiology of bile acids, the causes and symptoms of bile acid malabsorption, the diagnostic tests used to make the diagnosis and the treatment of this common but underdiagnosed condition. Should we use 'trial of treatment' in primary care to support the diagnosis? Are people who have had their gall bladder removed at greater risk of bile acid diarrhoea? Can bile acid sequestrants impact the absorption of other medications? These questions, and lots more, will be discussed in this episode. Key Learnings for Primary Care from this Ingest Podcast on Bile Acid Diarrhoea Overview and Prevalence Bile acid diarrhoea (BAD), also known as bile acid malabsorption, is a significant but under-recognized cause of chronic diarrhoea in primary care. It is more common than Crohn’s disease and ulcerative colitis combined, with a prevalence of about 1% in the general population-comparable to coeliac disease[1]. BAD is often misdiagnosed as IBS with diarrhoea (IBS-D); about one third of patients with IBS-D may actually have BAD[1]. Causes and Classification BAD is classified into three types: Type 1: Secondary to ileal disease or resection (e.g., Crohn’s disease, surgical removal of terminal ileum) Type 2: Primary or idiopathic (often confused with IBS-D; thought to be due to overproduction of bile acids) Type 3: Other causes affecting absorption, such as cholecystectomy, small intestinal bacterial overgrowth, or radiation[1]. Post-cholecystectomy BAD is relatively common, affecting about 1 in 10 patients after gallbladder removal[1]. Clinical Presentation Patients typically present with chronic, watery diarrhoea (Bristol stool types 6–7), often frequent (4–12 times daily), sometimes nocturnal, and can be long-standing (sometimes decades)[1]. There is often a long delay in diagnosis; nearly half of patients wait over five years for a correct diagnosis[1]. BAD is frequently overlooked in differential diagnosis, with clinicians more likely to investigate for IBD, coeliac disease, or cancer[1]. Diagnosis in Primary Care The key is to think about BAD as a possible diagnosis, especially in patients with chronic diarrhoea where other causes have been excluded[1]. The gold standard diagnostic test is the SeHCAT (selenium homocholic acid taurine) scan, which is widely available in the UK but not in all countries[1]. A retention value below 15% at seven days is diagnostic; lower values indicate more severe disease[1]. There is no simple blood test for BAD, unlike coeliac disease[1]. Empirical trials of bile acid sequestrants may be considered if SeHCAT is unavailable or in specific cases (e.g., pregnancy), but a confirmed diagnosis is preferred to guide treatment and improve adherence[1]. Before considering BAD, it is essential to exclude other causes of diarrhoea (negative coeliac serology, faecal calprotectin, and, depending on age, appropriate cancer screening)[1]. Treatment First-line treatment is with bile acid sequestrants: Cholestyramine : A powder taken in 4g sachets, usually started at night on an empty stomach for best effect (contrary to original cholesterol-lowering indications)[1].…

Ingest

1
Faecal calprotectin 37:24

2 years тому37:24

37:24

In this episode, Charlie Andrews speaks to Dr James Turvill about faecal calprotectin use in primary care. Dr Turvill is a gastroenterologist based in York, who was instrumental in developing the NICE-approved and widely adopted York Faecal Calprotectin Care Pathway. What is calprotectin? When should we use it in primary care? How should we interpret the result? Can any medications or conditions affect the result? Listen on to find the answers to these questions! The care pathway can be found here: https://www.yorkhospitals.nhs.uk/seecmsfile/?id=941 . It is recommended that you have a look at this either before, after or during this episode to enhance your learning. Enjoy!…

Ingest

1
IBS – dietary management and the 10-minute consultation… 38:38

2 years тому38:38

38:38

Marianne Williams is an extremely experienced dietician, innovator, digital technology advocate and winner of the NHS England Allied Health Professional of the Year prize for 2018. In this episode, Marianne shares her wealth of knowledge around all things IBS to discuss initial dietary management, the low FODMAPs diet, the role of probiotics, and gives us some great advice about how we can maximise our (often short) patient consultations with newly diagnosed IBS patients. Marianne also discusses her innovative dietetic-led gastroenterology clinic for IBS patients with us. There is so much food for thought here, and so many useful nuggets of information throughout this episode. Sit back and tuck into this feast of information! Useful links/websites discussed in the episode: Patient Webinars website: https://patientwebinars.co.uk/ Monash university IBS grand tour: https://www.youtube.com/watch?v=Z_1Hzl9o5ic Monash university app: https://www.monashfodmap.com/ibs-central/i-have-ibs/get-the-app/ IBS symptoms, the low FODMAP diet and the Monash app that can help See updated video for Irritable Bowel Syndrome (IBS) relief: Take the Monash University Low FODMAP grand tour down under! at https://www.youtube.com/watch?v=stdYoA4G9Dg See more: IBS patient course: https://www.monashfodmap.com/online-training/patients-course/ Website: https://www.monashfodmap.com/ Monash FODMAP blog: https://www.monashfodmap ... www.youtube.com BSG guidelines on the management of IBS: https://gut.bmj.com/content/gutjnl/early/2021/04/27/gutjnl-2021-324598.full.pdf…

Ingest

1
IBD Flare Management 26:44

2 years тому26:44

26:44

In this episode Charlie Andrews speaks to Dr Kevin Barrett about IBD flare management. On average, 50% of patients will flare annually, and often the GP surgery is the first port of call. We therefore need to know how to assess and manage patients presenting with symptomatic IBD. Kevin Barrett, IBD clinical champion for IBD for the RCGP and Crohns and Colitis UK (2017-2021) shares his wealth of knowledge about IBD flare management. We discuss how if can affect patient's quality of life, common symptoms of IBD flare, calprotectin testing and the management of IBD flare.…

Ingest

1
Updated guidance on FIT testing in primary care 31:26

2 years тому31:26

31:26

In this episode, Charlie Andrews speaks to Dr Kevin Monahan, lead author for the joint guidelines published by the BSG and ACPGBI in July 2022 outlining the role of FIT testing in patients with symptoms suggestive of colorectal cancer. These guidelines have informed how we use FIT in primary care, and in this episode he asks Dr Monahan how this guideline has changed clinical practice, they discuss when it should be used and what to do if you have ongoing concerns about your patient's symptoms. In addition, they discuss specific situations such as iron deficient anaemia, rectal bleeding, whether we can use it in younger age groups, and whether there is a role for repeat FIT testing. A link to the full guideline can be found here: https://www.bsg.org.uk/clinical-resource/faecal-immunochemical-testing-fit-in-patients-with-signs-or-symptoms-of-suspected-colorectal-cancer-crc-a-joint-guideline-from-the-acpgbi-and-the-bsg/…

Ingest

1
Abnormal LFTs and non-alcoholic liver disease 40:06

2 years тому40:06

40:06

Did you know that according to the British Liver Trust, up to 20% of the general population has non-alcoholic liver disease ('fatty liver disease') and the prevalence is predicted to rise over the coming years. Morbidity associated with this can be significant, with a proportion of patients with fatty liver disease developing fibrosis of the liver as the disease progresses. Diagnosing fatty liver disease and identifying those at risk of progression to fibrosis is therefore important. In this episode I speak to Dr Helen Jarvis, a GP with a specialist interest in liver disease. We discuss an approach to the patient with abnormal LFTs, and we look at the common causes of abnormal LFTs, with a particular focus on non-alcoholic fatty liver disease. Helen demystifies the commonly used tests for assessing for fibrosis in fatty liver disease, and how we can empower our nursing teams to assess for fatty liver disease when abnormal LFTs are identified at chronic disease reviews.…

Ingest

1
Coeliac disease management and follow-up 35:43

2 years тому35:43

35:43

Join Charlie Andrews in this episode where he speaks to Cristian Costas about the management of people diagnosed with coeliac disease. Cristian is a dynamic dietician who is based in Bradford. He is passionate about coeliac disease and runs an innovative dietician-led service for those with coeliac disease in his area. Cristian shares with us his top tips for supporting someone newly diagnosed with coeliac disease, including where to access support for those who are newly diagnosed, and how to avoid common dietary pitfalls. We discuss how best to follow-up people with coeliac disease, and key interventions such as assessments for osteoporosis and vaccinations for coeliacs. We know that education and the support of a dietician are key interventions that can help patients manage the gluten-free diet effectively, and in this episode, Cristian shares his passion for improving the care for those with coeliac disease. An informative, enjoyable and inspiring listen!…

Ingest

1
Background to FIT testing in primary care 31:27

2 years тому31:27

31:27

In primary care, we are increasingly using FIT (Faecal Immunochemical Testing) to assess the risk of bowel cancer in patients with lower gastrointestinal symptoms, whilst the latest PCN DES IIF (Impact and Investment Fund) has given FIT a prominent role in risk stratifying 2-week wait referrals to secondary care. In this episode, Mo Thoufeeq, a gastroenterologist in Sheffield, talks to me about what FIT is, how it differs from previously used FOBT (and why it is a more effective test!), and how we are using FIT in both symptomatic and asymptomatic patients. He shares his top tips about how to interpret, when to test and we discuss the tricky areas of patients with rectal bleeding and those with iron deficient anaemia. Mo has a deep knowledge and understanding of FIT and provides a fantastic and relevant discussion of the topic for our primary care audience in this episode.…

Ingest

1
Bridging the gap between primary and secondary care in inflammatory bowel disease (IBD) 31:50

3 years тому31:50

31:50

In this episode, I am joined by Pearl Avery. Pearl has a unique role - she spends part of her week as an IBD nurse specialist, and part of her week as an ANP (Advanced Nurse Practitioner) working in a GP practice. Pearl has a fantastic understanding of both primary and secondary care and shares her experiences with me. We discuss her unique and innovative role, common queries from GPs and patients from her IBD nurse specialist role (including common questions about flare management and biologic monitoring), and what she has learned about the care of people with IBD from her primary care role. I felt extremely energised and enthusiastic after speaking to Pearl and took home some great top tips. This episode really demonstrates the benefit of working collaboratives and 'bridging the gap' between primary and secondary care.…

Ingest

1
Inflammatory Bowel Disease (IBD) 34:34

3 years тому34:34

34:34

I speak to Chris Lamb about IBD. Chris was lead author on the BSG IBD guidelines which were published in 2019. The full guidance can be found here: BSG-IBD-Guidelines-2019.pdf Chris is a fount of knowledge for all things related to IBD and I have a fascinating chat with him about the guidance and how these relate to primary care - we range over all aspects of IBD from diagnosis to management and everything in between.…

Ingest

1
Chronic diarrhoea 42:25

3 years тому42:25

42:25

In this episode, I speak to Professor Ramesh Arasaradnam. Ramesh co-authored the BSG guidelines on chronic diarrhoea in 2018, and is a fount of knowledge in this area.

Ingest

1
Functional Dyspepsia 28:04

3 years тому28:04

28:04

Affecting up to 20% of the UK population, dyspepsia is commonly seen in primary care. Following investigations, the majority of people (up to 89%) are found to have functional dyspepsia. As with any functional problem of the gut, such as IBS, making a confident diagnosis is sometimes challenging but extremely important for the patient, and management encompasses a range of non-pharmacological interventions. Pali Hungin, an extremely experienced primary care clinician and a founding member of both the PCSG and it’s European counterpart, shares his vast experience and understanding of functional dyspepsia with us in this episode. As chair of the ROME VI primary care committee, Pali is hugely knowledgeable about this complex yet common condition.…

Ingest

1
H. Pylori 56:29

3 years тому56:29

56:29

This edition of the podcast series Ingest published by the Primary Care Society for Gastroenterology (PCSG) features a very special guest from the world of gastroenterology. Dr Charlie Andrews talks to Nobel Prize laureate Professor Barry Marshall, the Director of the Marshall Centre founded in 2007 in his honour, the Western Australian Ambassador for Life Sciences and University of WA Brand Ambassador, about his discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease. Key Learnings from the Podcast What is Helicobacter pylori? H. pylori is a microaerophilic bacterium that resides in the mucous layer of the stomach lining, not invading the bloodstream, which explains why even immunosuppressed patients do not develop sepsis from it. It is classified as a Class 1 carcinogen by the WHO due to its established role in gastric cancer, and it is a primary cause of gastritis and peptic ulcer disease, alongside NSAID use[1]. Historical Context and Impact The discovery of H. pylori by Marshall and Warren in the early 1980s overturned the previous belief that the stomach was sterile and that ulcers were caused mainly by stress or lifestyle factors. Their work demonstrated that a common bacterial infection was the main cause of most gastritis and peptic ulcer disease, leading to a dramatic decline in ulcer surgeries and transforming ulcer management[1]. The link between H. pylori and gastric cancer was established epidemiologically: areas with high H. pylori prevalence have higher rates of stomach cancer[1]. Diagnosis in Primary Care Available Tests: Test TypeWhat it DetectsPros & ConsSerology (Blood)Antibodies to H. pyloriHighly sensitive; good for ruling out H. pylori if negative; can remain positive after eradication, so less useful for confirming active infection[1].Urea Breath TestActive infectionHighly specific for current infection; preferred in Australia for confirmation; fewer false positives[1].Stool Antigen TestActive infectionAlso highly specific; convenient for children; widely used in UK primary care[1]. Best Practice: Use stool antigen or breath test to confirm active infection, especially before starting eradication therapy. Serology is useful as a rule-out test-if negative, H. pylori infection is unlikely[1]. Caveat: Serology may remain positive for a year or more after eradication, so it should not be used to confirm cure or active infection[1]. Treatment Considerations Once diagnosed, H. pylori infection is treatable with antibiotics, which is satisfying for both clinicians and patients as it offers a clear cure pathway[1]. There is ongoing debate about whom to treat: treat symptomatic patients (e.g., with ulcers or dyspepsia) rather than universally treating all who test positive, especially given increasing antibiotic resistance[1]. The advent of proton pump inhibitors (PPIs) combined with antibiotics in the 1990s significantly improved cure rates, making outpatient management by GPs routine[1]. Epidemiological Trends and Clinical Implications The prevalence of H. pylori has declined in developed countries, but remains high in some regions and populations. In the current era, not all ulcers are due to H. pylori-NSAID-induced ulcers are now common, and gastroesophageal reflux disease (GERD) is more prevalent in Western countries[1]. A careful history (birthplace, family history of ulcers, etc.) can help estimate H. pylori risk before testing[1].…

Ingest

1
Dyspepsia 31:06

3 years тому31:06

31:06

Dyspepsia is a common presenting complaint in primary care, and encompasses a range of symptoms including GORD, nausea, and epigastric pain. Having an approach to these patients is vital given how commonly we see these symptoms, and Mike Burkitt joins me in this episode to provide a really useful overview of dyspepsia, and how we can approach this symptom in clinical practice. Mike also gives his thoughts on what to do when the endoscopy comes back normal in a symptomatic patient. Useful resources for dyspepsia include: https://cks.nice.org.uk/topics/dyspepsia-unidentified-cause/ https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#upper-gastrointestinal-tract-cancers A great video recorded by Dr Sophie Nelson and Dr Mike Burkitt covering dyspepsia can be found here: https://mft.nhs.uk/mri/services/gastroenterology-and-hepatology/…

Ingest

1
Coeliac Disease 30:40

3 years тому30:40

30:40

Dr Charlie Andrews discusses coeliac disease. Following the last episode on iron deficiency anaemia this episode focuses on coeliac disease, what it is, NICE guidance, when to suspect, how to test and a non biopsy pathway to diagnosis. First though a history lesson ......

Ingest

1
Iron Deficiency Anaemia 34:45

3 years тому34:45